NewsUp one level
After an interview with its previous chairman last year, the ETPN continues to contribute to the European research report called International Innovation. The article written by the ETPN secretariat is to be published as the last word of the June 2013 issue and is presenting the potential of nanotechnologies in healthcare.
Is nanomedicine the next big thing? A growing number of top drug companies seem to think so.
AstraZeneca and BIND Therapeutics announce worldwide development and commercialisation agreement for cancer nanomedicine
BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and Commercialize Multiple Accurins™
BIND Eligible to Receive Approximately $50 Million in Upfront and Development Milestone Payments Plus Additional Regulatory and Sales Milestones and Royalties for Each Accurin
Nanonica, a company focusing on added value transforming ideas into marketable products, has just launched a Nanotechnology Prize initiative. The award has two categories: 1.- Breakthrough of the year: chosen by a scientific committee (10000 €) 2.- Best applied proposal: to be submitted by the 30th of August 2013
The event "Advanced Summer School Interrogations at the Biointerface - Inflammation/Repair Interface", takes place in Porto, Portugal, from the 25th to the 28th of June 2013.
Get the latest insights into the recent ETPN and NanoMed 2020 activities
In the framework of the World Cancer Day, the European Technology Platform on Nanomedicine (ETPN) and its partners have organised on 1st February 2013 a European event dedicated to nanomedicine contributions for cancer. Intitled “Small tools for a big cause: How nanomedicine contributes to better cancer diagnostic and therapy”, this multi-sites concept took place in Germany, France and Portugal and highlighted the importance of nanomedicine research for cancer on the European level.
The NANOMED2020 Coordination and Support Action under the FP7-Health aims at delivering concrete recommendations to the European Commission to push forward the field of nanomedicine under Horizon 2020.
The ERA-NET EuroNanoMed II launches a fourth Joint Call for Proposals to support transnational innovative research projects in Nanomedicine. This call is open from December 10th 2012, with a submission deadline of March 4th 2013
INEB Coordinates the new IB2 NETWORK launched under the Marie Curie Programme (Initial Training Network).
Selection process open until 31th January 2013!
The election for the chairperson of the ETP Nanomedicine has been opened from 16th to 30th November 2012 for the ETPN Members. Please find herewith the results of the vote.
Following the adoption of the definition of the term 'nanomaterial' in October 2011, this report identifies relevant measurement methods and key challenges for measuring nanoparticle size in the regulatory context.
Four Early Stage Researcher positions (PhD) - Marie Curie-ITN-EID: Industrial Biological Biomaterials Doctorate
INEB and the IB2 Network are looking for exceptionally talented and motivated researchers, capable of working in both academic and industrial environments, with a positive, entrepreneurial attitude.
Companies, R&D teams and individuals are invited, the feedback will be helpful to improve and refine the roadmap together with the European Commission.
As the potential global benefits offered by nanomedicines grow each year, the British Society for Nanomedicine has been created to help industry, academia and the public stay abreast of the latest research and developments in this emerging area of science.
The FP7-Call 2013 for IAPP is open till 16th January 2013 with 81 Million Euro reserved for the exchange of knowledge
The fourth edition of the Biocapsules will be held in Barcelona with 5 dates on different topics such as start-ups valuation in international environment, strategic communication, strategic management of intellectual property, project management with highly qualified teams and business development
The ETPN General Assembly 2012 and Thematic circles on Nanomedicine will take place in London on 30th and 31st October 2012.
Consultation on plans for a public-private partnership in life sciences research and innovation under Horizon 2020
The European Commission launched a public consultation to seek key views relating to the launch of a PPP in the life sciences research area under Horizon 2020 and what areas should be addressed. The planned PPP would implement part of the "health, demographic change and wellbeing" challenge. The consultation is open to all citizens and organisations, contributions from companies, organisations and researchers active in life sciences research and innovation are particularly sought. Deadline for contributions is on 04.10.2012.
Deadline: 31st October 2012. Open Access to nano and micro technologies.
The nanomedicine was shown to concentrate activity in the tumor up to 10 times higher than conventional chemotherapy treatment options.